Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:38:11.374Z.
Calculation as of: 2026-10-06T20:38:11.374Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 77ffd79d43f0055242b38282a97f53e69ef3ec7586b4a3f7de15a7f16befe37a
PE RATIO
N/A
SpyGlass Pharma, Inc. Common Stock
Market Cap
$828.48M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$833.81M
PE Ratio
N/A
TTM Avg
76.88
3Y Avg
76.88
5Y Avg
76.88
Market Cap
$838.62M
PE Ratio
N/A
TTM Avg
351.06
3Y Avg
351.06
5Y Avg
351.06
Market Cap
$853.13M
PE Ratio
2.83
TTM Avg
3.74
3Y Avg
21.90
5Y Avg
21.90
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SpyGlass Pharma, Inc. Common Stock (SGP) | $828.48M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | N/A | 76.88 | 76.88 | 76.88 |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | N/A | 351.06 | 351.06 | 351.06 |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | N/A | 197.34 | 197.34 | 197.34 |
| Jade Biosciences, Inc. (JBIO)vs › | $816.13M | N/A | N/A | N/A | N/A |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $804.16M | 11.37 | 9.51 | 9.54 | 15.29 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 2.83 | 3.74 | 21.90 | 21.90 |
| Alumis Inc. (ALMS)vs › | $855.38M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$24.78
Forward EPS (Est.)
$-2.50
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
